Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16910470 | 0.75 | KDM4C (0.49) | KDM4CL3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1128388 | 0.72 | — | — | |
| SCHEMBL1983146 | 0.71 | NISCH (0.45) | KDM4CNPC1ALDH1A1TAAR1LTA4H | |
| SCHEMBL11603668 | 0.70 | KDM4C (0.48) | KDM4CLTA4HTSHRGPR84 | |
| SCHEMBL9909763 | 0.69 | BRAF (0.53) | BRAF | |
| SCHEMBL9909765 | 0.69 | BRAF (0.57) | BRAF | |
| SCHEMBL1133436 | 0.67 | GAA (0.50) | NPC1ALDH1A1TP53HPGDL3MBTL1 | |
| Diphenylether SCHEMBL8548398 | 0.67 | LTA4H (0.44) | NPC1HPGDLTA4HTSHRXDH | |
| SCHEMBL17959987 | 0.66 | TSHR (0.38) | KMT2ALTA4HTSHRNTRK1NTRK3 | |
| SCHEMBL3518864 | 0.66 | KDR (0.49) | NPC1ALDH1A1L3MBTL1SMN1; SMN2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104292229-A | 2-phenoxy pyrimidinone analogues | NEUROGEN CORP | 2015-01-21 | — | — | CN | disclosed |
| CN-104292229-A | 2-phenoxy pyrimidinone analogues | NEUROGEN CORP | 2015-01-21 | — | — | CN | disclosed |
| US-8759361-B2 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759361-B2 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2014-06-24 | — | — | US | disclosed |
| EP-2061794-B1 | 2-PHENOXY PYRIMIDINONE ANALOGUES | NEUROGEN CORP (US) | 2012-12-05 | — | — | EP | disclosed |
| US-20120208829-A1 | 2-PHENOXY PYRIMIDINONE ANALOGUES | NEUROGEN CORPORATION (US) | 2012-08-16 | — | — | US | disclosed |
| US-8003656-B2 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003656-B2 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2011-08-23 | — | — | US | disclosed |
| CN-101506210-A | 2-Phenoxypyrimidinone analogs | NEUROGEN CORP (US) | 2009-08-12 | — | — | CN | disclosed |
| CN-101506210-A | 2-Phenoxypyrimidinone analogs | NEUROGEN CORP (US) | 2009-08-12 | — | — | CN | disclosed |
| EP-2061794-A2 | 2-PHENOXY PYRIMIDINONE ANALOGUES | Neurogen Corporation (US) | 2009-05-27 | — | — | EP | disclosed |
| EP-2061794-A2 | 2-PHENOXY PYRIMIDINONE ANALOGUES | Neurogen Corporation (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20090069347-A1 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069347-A1 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| WO-2008024438-A3 | 2-PHENOXY PYRIMIDINONE ANALOGUES | NEUROGEN CORP (US) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008024438-A2 | 2-PHENOXY PYRIMIDINONE ANALOGUES | NEUROGEN CORPORATION (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024438-A2 | 2-PHENOXY PYRIMIDINONE ANALOGUES | NEUROGEN CORPORATION (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208829-A1 | 2-PHENOXY PYRIMIDINONE ANALOGUES | GPR174, GPR17, PTGFR | KDM4C 3426/4885NPC1 2715/4885ALDH1A1 920/4885 |
| US-20090069347-A1 | 2-phenoxy pyrimidinone analogues | GPR174, GPR17, PTGFR | KDM4C 3426/4885NPC1 2715/4885ALDH1A1 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.